Amantadine, oseltamivir and zanamivir for the treatment of influenza

Influenza - zanamivir, amantadine and oseltamivir (review): review decision - November 2014 information

Influenza - zanamivir, amantadine and oseltamivir (review): appendix A - GE decision paper - October 2014

Influenza - zanamivir, amantadine and oseltamivir (review): appendix A - GE decision paper - October 2014 (PDF 290 KB)

Review Proposal - June 2014 information

Appendix A - provisional matrix of stakeholders

Appendix A - provisional matrix of stakeholders (PDF 103 KB)

Appendix B - addendum to the review considerations for TA158 and TA168

Appendix B - addendum to the review considerations for TA158 and TA168 (PDF 146 KB)

Appendix C - consultee and commentator comments on TA168 proposal

Appendix C - consultee and commentator comments on TA168 proposal (PDF 102 KB)

TA168 Influenza - zanamivir, amantadine and oseltamivir (review): review proposal - November 2013 information

TA168 Influenza - zanamivir, amantadine and oseltamivir (review): Appendix A - provisional matrix of stakeholders

TA168 Influenza - zanamivir, amantadine and oseltamivir (review): Appendix A - provisional matrix of stakeholders (PDF 102 KB)

TA168 Influenza - zanamivir, amantadine and oseltamivir (review): Appendix B - proposal paper presented to the Institute's Guidance Executive

TA168 Influenza - zanamivir, amantadine and oseltamivir (review): Appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 612 KB)

Influenza - zanamivir, amantadine and oseltamivir (review): final appraisal determination (FAD) information

Influenza - zanamivir, amantadine and oseltamivir (review): Final appraisal determination

Influenza - zanamivir, amantadine and oseltamivir (review): Final appraisal determination (PDF 126 KB)

Influenza - zanamivir, amantadine and oseltamivir (review): Response to consultee, commentator and website comments on the Appraisal Consultation Document - prepared by the Technical Lead, Rebecca Trowman

Influenza - zanamivir, amantadine and oseltamivir (review): Response to consultee, commentator and website comments on the Appraisal Consultation Document - prepared by the Technical Lead, Rebecca Trowman (PDF 51 KB)

Influenza - zanamivir, amantadine and oseltamivir (review): Additional scenario analyses carried out by the Assessment Group

Influenza - zanamivir, amantadine and oseltamivir (review): Additional scenario analyses carried out by the Assessment Group (PDF 19 KB)

Influenza - zanamivir, amantadine and oseltamivir (review): Consultee and commentator comments on the ACD

GlaxoSmithKline

GlaxoSmithKline (PDF 11 KB)

Roche

Roche (PDF 19 KB)

British Thoracic Society

British Thoracic Society (PDF 13 KB)

Diabetes UK

Diabetes UK (PDF 38 KB)

Royal College of Paediatricians and Child Health

Royal College of Paediatricians and Child Health (PDF 61 KB)

Department of Health

Department of Health (PDF 11 KB)

Welsh Assembly Government

Influenza - zanamivir, amantadine and oseltamivir (review): appraisal consultation

Influenza - zanamivir, amantadine and oseltamivir (review): appraisal consultation document information

Influenza - zanamivir, amantadine and oseltamivir (review): overview

Influenza - zanamivir, amantadine and oseltamivir (review): overview (PDF 129 KB)

Influenza - zanamivir, amantadine and oseltamivir (review): assessment report

Influenza - zanamivir, amantadine and oseltamivir (review): assessment report (PDF 8.19 MB)

Consultee and commentator comments on the assessment report

Consultee and commentator comments on the assessment report: British Thoracic Society

Consultee and commentator comments on the assessment report: British Thoracic Society (PDF 13 KB)

Consultee and commentator comments on the assessment report: Diabetes UK

Consultee and commentator comments on the assessment report: Diabetes UK (PDF 39 KB)

Consultee and commentator comments on the assessment report: GlaxoSmithKline

Consultee and commentator comments on the assessment report: GlaxoSmithKline (PDF 17 KB)

Consultee and commentator comments on the assessment report: Roche Products

Consultee and commentator comments on the assessment report: Roche Products (PDF 68 KB)

Consultee and commentator comments on the assessment report: Royal College of Paediatrics and Child Health

Consultee and commentator comments on the assessment report: Royal College of Paediatrics and Child Health (PDF 21 KB)

Non-manufacturer submissions

Non-manufacturer submissions: British Thoracic Society

Non-manufacturer submissions: British Thoracic Society (PDF 53 KB)

Non-manufacturer submissions: Health Protection Agency

Non-manufacturer submissions: Health Protection Agency (PDF 27 KB)

Manufacturer submissions

Manufacturer submission: GlaxoSmithKline

Manufacturer submission: GlaxoSmithKline (PDF 15 KB)

Manufacturer submission: Roche Products

Manufacturer submission: Roche Products (PDF 32 KB)

Expert witness personal statements

Expert witness personal statements: Dr Will Carroll

Expert witness personal statements: Dr Will Carroll (PDF 32 KB)

Expert witness personal statements: Dr Wei Shen Lim

Expert witness personal statements: Dr Wei Shen Lim (PDF 46 KB)

Expert witness personal statements: Prof. Maria Zambon

Influenza - zanamivir, amantadine and oseltamivir: final scope

Influenza - zanamivir, amantadine and oseltamivir: final matrix of consultees and commentators

Influenza - zanamivir, amantadine and oseltamivir: consultees and commentators responses on the draft scope

Influenza - zanamivir, amantadine and oseltamivir - provisional matrix of consultees and commentators

Influenza - zanamivir, amantadine and oseltamivir: draft scope